HER2 Non-Small Cell Lung Cancer Epidemiology Forecast 2025-2034

HER2 Non-Small Cell Lung Cancer Epidemiology Forecast Report Coverage

Expert Market Research's “HER2 Non-Small Cell Lung Cancer Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of HER2 non-small cell lung cancer. It projects the future incidence and prevalence rates of HER2 non-small cell lung cancer across various populations. The study covers age and type as major determinants of the HER2 non-small cell lung cancer-affected population. The report highlights patterns in the prevalence of HER2 non-small cell lung cancer over time and projects future trends based on multiple variables.

HER2 Non-Small Cell Lung Cancer Disease Overview

The human epidermal growth factor receptor 2 (HER2) gene is overexpressed or mutated in HER2-positive non-small cell lung cancer (NSCLC), a subtype of lung cancer. These changes, which cause unchecked cell growth, occur in about 1% to 3% of NSCLC cases. Nonsmokers and people with adenocarcinoma histology are more likely to have HER2 mutations.

HER2 Non-Small Cell Lung Cancer Treatment Overview

Targeted therapies that specifically target HER2 alterations are part of the treatment for HER2-positive non-small cell lung cancer (NSCLC). In patients with HER2 mutations, the antibody-drug conjugate trastuzumab deruxtecan has shown notable effectiveness. Tyrosine kinase inhibitors (such as neratinib and poziotinib) and chemotherapy are additional treatment options for more comprehensive disease control. Although its effectiveness in HER2-positive cases is still being investigated, immunotherapy may also be taken into consideration. The type of HER2 alteration, the cancer's stage, and the patient's general health are some of the factors that go into choosing a treatment. Clinical trials are still a crucial tool for investigating new treatments. Patients with this aggressive cancer type now have more options than chemotherapy thanks to targeted therapies like HER2 inhibitors.

Epidemiology

The HER2 non-small cell lung cancer epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for HER2 non-small cell lung cancers by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for HER2 non-small cell lung cancer and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• As per the Translational Lung Cancer Research's recent studies on HER2 mutations, NSCLC were reported mostly in Asian patient populations where the percentage of lung cancer patients who have never smoked is higher by about 30% than in North American and European populations with 10%.
• Patients with adenocarcinoma non-small cell lung cancer who have little to no history of smoking are more likely to have HER2 mutations. HER2 mutations are found in about 2% of patients with lung cancer.
• According to an article published in ScienceDirect, patients with HER2-mutated non-small cell lung cancer (NSCLC) usually have a median age of 65 years old.

Country-wise HER2 Non-Small Cell Lung Cancer Epidemiology

The HER2 non-small cell lung cancer epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of HER2 non-small cell lung cancers varies significantly between countries due to differences in factors such as hygiene practices and genetic factors, among others. In the United States, 1–6.7% of cases of non-small cell lung cancer (NSCLC) have HER2 alterations. HER2 mutation, amplification, and overexpression are among these changes.

Country Specific Stats:

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, and treatment options of HER2 non-small cell lung cancer based on several factors.
• HER2 Non-Small Cell Lung Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of HER2 non-small cell lung cancers are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of HER2 non-small cell lung cancer epidemiology in the 8 major markets?
• What will be the total number of patients with HER2 non-small cell lung cancer across the 8 major markets during the forecast period?
• What was the country-wise prevalence of HER2 non-small cell lung cancer in the 8 major markets in the historical period?
• Which country will have the highest number of HER2 non-small cell lung cancer patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of HER2 non-small cell lung cancer during the forecast period of 2025-2034?
• What are the currently available treatments for HER2 non-small cell lung cancer?
• What are the disease risks, signs, symptoms, and unmet needs of HER2 non-small cell lung cancer?

Related Reports

Small Cell Lung Cancer (SCLC) Market

Global Non-Small Cell Lung Cancer Treatment Market